等待开盘 08-15 09:30:00 美东时间
+0.036
+5.19%
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, will release its Q2 2025 financial results and host a webcast/conference call on Monday, August 11, 2025, at 8:00 AM ET. The event will provide updates on the tovecimig Phase 2/3 study, clinical data for CTX-8371, and preclinical data for CTX-10726. The call can be accessed via dial-in numbers 1-877-407-9716 (US) or 1-201-493-6779 (Intl.), using conference ID 13754...
08-08 20:01
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price target from $5 to $4.
08-07 18:57
Context Therapeutics reported Q2 2025 financial results with $83.5 million in cash and expects to fund operations into 2027. The company is advancing its T cell engaging bispecific antibody pipeline, including CTIM-76 and CT-95, with initial data expected in 2026. Notable updates include CT-95's first patient dosing and presentations at major oncology conferences. R&D expenses rose to $7.8 million due to pipeline expansion and higher personnel co...
08-06 20:11
<p>Concentrix Corporation has launched the latest version of iX Hero, part of its Intelligent Experience product suite, featuring new capabilities Harmony and Clarity. These enhancements利用先进的AI技术提升客户互动的清晰度和背景噪音抑制,显著提升了客户沟通分数和净推荐分数。客户PODS表示,使用iX Hero后销售转化率大幅提升。Concentrix高管强调,这些功能助力客户进入新市场并优化全球团队。产品现全球可用,并针对菲律宾、印度和拉美团队进行了优化。</p>
07-30 20:05
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德:维持HIVE Digital Technologies(HIVE)"超配"评级,目标价从5美元升至5.5美元</p> <p>• BTIG:维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
今日重点评级关注:Benchmark:维持特斯拉(TSLA)"买入"评级,目标价从350美元升至475美元>>
06-27 08:37
Piper Sandler analyst Biren Amin reiterates Context Therapeutics (NASDAQ:CNTX) with a Overweight and lowers the price target from $4.5 to $4.
06-27 00:40
Candel Therapeutics agreed to sell approximately 3.2 million shares at $4.67 per share in a registered direct offering, raising about $15 million. Proceeds will support CAN-2409's pre-commercialization and launch readiness for prostate cancer, pending FDA approval. Candel highlighted its multimodal immunotherapy platforms, successful clinical trials for CAN-2409, and multiple FDA designations, including Fast Track, RMAT, and Orphan Drug. The comp...
06-24 13:05
Context Therapeutics Inc. announced the presentation of a Trial in Progress poster for the Phase 1 clinical trial of CTIM-76, a CLDN6 x CD3 T cell engager, targeting ovarian, endometrial, and testicular cancers at the 2025 ASCO Annual Meeting. The Phase 1 trial, which started dosing in January 2025 and is currently in Cohort 3, aims to assess the safety, tolerability, and efficacy of CTIM-76 in CLDN6-positive solid tumors. Initial data is expecte...
06-02 11:30
<p>Context Therapeutics Inc. announced the appointment of Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025. Dr. Chagin, with over a decade of experience in T cell therapy development, succeeds interim CMO Dr. Karen Smith. She previously led clinical teams at Adaptimmune and Tmunity, contributing to the approval of Tecelra®. The company granted Dr. Chagin 153,000 stock options as an inducement for her employment, vesting over four...
05-29 11:30